Susquehanna International Group
AVBP icon

Susquehanna International Group’s ArriVent BioPharma AVBP Stock Holding History

Susquehanna International Group’s Portfolio AVBP Stock Details AVBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$3.02M Buy
+131,000
New +$2.96M ﹤0.01% 5252

Other funds holding AVBP

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
IAM
Infinitum Asset Management Fort Lauderdale, Florida $801M AUM 8.83% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Susquehanna International Group's AVBP Position: Q1 2026 in Review

Susquehanna International Group reduced its ArriVent BioPharma (AVBP) stake by 87% in Q1 2026, selling an estimated $4.79M and leaving 30,898 shares worth $713K. The position accounts for ﹤0.01% of the portfolio, ranked #8773.

Susquehanna International Group first reported a position in AVBP in Q4 2024 and has held it in 5 quarters since. The position peaked at $4.89M in Q4 2025. 139 funds tracked by Wall St. Rank hold AVBP as of Q1 2026.

  • Susquehanna International Group held 30,898 shares of ArriVent BioPharma worth $713K as of Q1 2026.
  • Susquehanna International Group sold 211,930 ArriVent BioPharma shares in Q1 2026, an estimated $4.79M.
  • ArriVent BioPharma made up ﹤0.01% of Susquehanna International Group's portfolio in Q1 2026, its #8773 holding.
  • Susquehanna International Group first reported a position in ArriVent BioPharma in Q4 2024 and has held it in 5 quarters since.
  • Susquehanna International Group's ArriVent BioPharma position peaked at $4.89M in Q4 2025.
  • 139 funds tracked by Wall St. Rank held ArriVent BioPharma as of Q1 2026.

Based on Susquehanna International Group's 13F filing for Q1 2026, filed 15 May 2026.